|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We therefore investigated a role for IGF-1R and t-Darpp in regulating glycolytic capacity in HER2<sup>+</sup> breast cancers.<b>Experimental Design:</b> We examined the relationship between t-Darpp and IGF-1R expression in breast tumors and their respective relationships with patient survival.
|
29180608 |
2018 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results suggest that dysregulation of the IGF-IR IRES through changes in the activities of RNA-binding translation-regulatory proteins could be responsible for IGF-IR overexpression in a proportion of human breast tumors.
|
18452152 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results further support a role of GH/IGF-I in regulating mammary tumorigenesis but suggest the ultimate consequences of GH/IGF-I on breast tumor development are dependent on the diet and/or metabolic status.
|
25085903 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore, IGF-IR overexpression in murine mammary epithelial cells induces mammary tumors with primarily basal-like characteristics, whereas tumors that develop following IGF-IR downregulation express a gene signature that most closely resembles human claudin-low breast tumors.
|
22020329 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells.
|
15548698 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The insulin-like growth factors IGF-I and IGF-II are potent mitogens for several breast tumor cell lines in culture.
|
2152773 |
1990 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development.
|
17082888 |
2007 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The aim of this case-control study was the comparison of serum activins, follistatins, and members of the IGF family levels in women with benign vs malignant breast neoplasms vs apparently healthy controls.
|
30388235 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Since many breast tumors and cancer cell lines overexpress IGF-IR, we tested IGF-I effects on chemotherapy-treated breast cancer cells.
|
12555073 |
2003 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Resveratrol inhibits migration and invasion of human breast-cancer cells.
|
18398872 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer.
|
16161053 |
2006 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).
|
18375957 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer.
|
15986122 |
2005 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our findings were substantiated in a cohort of breast tumors in which IGF-1R expression was positively correlated with ERα/Src and ERα/PI3K expression, hallmarks of nongenomic estrogen signaling, reinforcing the link between IGF-1R and mERα.
|
30692633 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Next, we used GPER-positive but estrogen receptor (ER)-negative primary CAF cells derived from patient breast tumours and SKBR3 breast cancer cells to investigate the role of GPER in the regulation of VEGF expression and angiogenesis triggered by IGF1.
|
29212519 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer.
|
18762812 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
|
18045956 |
2007 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.
|
18757322 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
|
17010055 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
|
15756256 |
2005 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells.
|
17166846 |
2007 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In general, lesser amounts of IGF-I mRNA were detected in fibroblasts derived from breast tumors or skin.
|
7757999 |
1995 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, a breast tumor-derived signature of high IGF-1 ligand is associated with favorable outcome, in contrast to a previously reported IGF-IR activation signature.
|
22297468 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, we review the rationale for targeting the IGF-1 system in the different BrCa molecular subtypes and in treatment resistant breast tumors with a focus on both the molecular mechanisms and on the clinical perspectives of such approaches in specific population subgroups.
|
29253837 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, inhibitors to the AKT/IGF-1R signaling pathways may provide alternative approaches to block escape pathways and restore hormone sensitivity in resistant breast tumors.
|
25178514 |
2014 |